Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

NCT03770273 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Indolent Systemic Mastocytosis

Interventions

BIOLOGICAL: sarilumab
OTHER: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)